241 related articles for article (PubMed ID: 21659759)
1. Advanced glycation end products.
Thomas MC
Contrib Nephrol; 2011; 170():66-74. PubMed ID: 21659759
[TBL] [Abstract][Full Text] [Related]
2. Advanced glycation end products and diabetic nephropathy.
Thomas MC; Forbes JM; Cooper ME
Am J Ther; 2005; 12(6):562-72. PubMed ID: 16280650
[TBL] [Abstract][Full Text] [Related]
3. Role of AGEs in diabetic nephropathy.
Fukami K; Yamagishi S; Ueda S; Okuda S
Curr Pharm Des; 2008; 14(10):946-52. PubMed ID: 18473844
[TBL] [Abstract][Full Text] [Related]
4. Advanced glycosylation end products in diabetic renal and vascular disease.
Bucala R; Vlassara H
Am J Kidney Dis; 1995 Dec; 26(6):875-88. PubMed ID: 7503061
[TBL] [Abstract][Full Text] [Related]
5. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
[TBL] [Abstract][Full Text] [Related]
6. Chrysin Inhibits Advanced Glycation End Products-Induced Kidney Fibrosis in Renal Mesangial Cells and Diabetic Kidneys.
Lee EJ; Kang MK; Kim DY; Kim YH; Oh H; Kang YH
Nutrients; 2018 Jul; 10(7):. PubMed ID: 29987200
[TBL] [Abstract][Full Text] [Related]
7. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets.
Sourris KC; Forbes JM
Curr Drug Targets; 2009 Jan; 10(1):42-50. PubMed ID: 19149535
[TBL] [Abstract][Full Text] [Related]
8. Loganin attenuates diabetic nephropathy in C57BL/6J mice with diabetes induced by streptozotocin and fed with diets containing high level of advanced glycation end products.
Liu K; Xu H; Lv G; Liu B; Lee MK; Lu C; Lv X; Wu Y
Life Sci; 2015 Feb; 123():78-85. PubMed ID: 25623853
[TBL] [Abstract][Full Text] [Related]
9. Advanced glycation end-products in diabetic nephropathy.
Sugiyama S; Miyata T; Horie K; Iida Y; Tsuyuki M; Tanaka H; Maeda K
Nephrol Dial Transplant; 1996; 11 Suppl 5():91-4. PubMed ID: 9044316
[TBL] [Abstract][Full Text] [Related]
10. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease.
Thomas MC; Baynes JW; Thorpe SR; Cooper ME
Curr Drug Targets; 2005 Jun; 6(4):453-74. PubMed ID: 16026265
[TBL] [Abstract][Full Text] [Related]
11. Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?
Zhuang A; Forbes JM
Glycoconj J; 2016 Aug; 33(4):645-52. PubMed ID: 27270766
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycation end products and the kidney.
Bohlender JM; Franke S; Stein G; Wolf G
Am J Physiol Renal Physiol; 2005 Oct; 289(4):F645-59. PubMed ID: 16159899
[TBL] [Abstract][Full Text] [Related]
13. RAGE-Aptamer Blocks the Development and Progression of Experimental Diabetic Nephropathy.
Matsui T; Higashimoto Y; Nishino Y; Nakamura N; Fukami K; Yamagishi SI
Diabetes; 2017 Jun; 66(6):1683-1695. PubMed ID: 28385802
[TBL] [Abstract][Full Text] [Related]
14. Advanced glycation endproducts and diabetic nephropathy.
Makita Z; Yanagisawa K; Kuwajima S; Yoshioka N; Atsumi T; Hasunuma Y; Koike T
J Diabetes Complications; 1995; 9(4):265-8. PubMed ID: 8573743
[TBL] [Abstract][Full Text] [Related]
15. Advanced glycation end products (AGEs) increase renal lipid accumulation: a pathogenic factor of diabetic nephropathy (DN).
Yuan Y; Sun H; Sun Z
Lipids Health Dis; 2017 Jun; 16(1):126. PubMed ID: 28659153
[TBL] [Abstract][Full Text] [Related]
16. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions.
Sanajou D; Ghorbani Haghjo A; Argani H; Aslani S
Eur J Pharmacol; 2018 Aug; 833():158-164. PubMed ID: 29883668
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?
Coughlan MT; Thallas-Bonke V; Pete J; Long DM; Gasser A; Tong DC; Arnstein M; Thorpe SR; Cooper ME; Forbes JM
Endocrinology; 2007 Feb; 148(2):886-95. PubMed ID: 17110423
[TBL] [Abstract][Full Text] [Related]
18. Glycation in diabetic nephropathy.
Forbes JM; Cooper ME
Amino Acids; 2012 Apr; 42(4):1185-92. PubMed ID: 20963456
[TBL] [Abstract][Full Text] [Related]
19. Clinical review: The role of advanced glycation end products in progression and complications of diabetes.
Goh SY; Cooper ME
J Clin Endocrinol Metab; 2008 Apr; 93(4):1143-52. PubMed ID: 18182449
[TBL] [Abstract][Full Text] [Related]
20. Advanced glycation end products in the pathogenesis of chronic kidney disease.
Rabbani N; Thornalley PJ
Kidney Int; 2018 Apr; 93(4):803-813. PubMed ID: 29477239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
